Immuneoncia Therapeutics Inc.
Clinical trials sponsored by Immuneoncia Therapeutics Inc., explained in plain language.
-
New drug aims to shrink hard-to-treat tumors in 30 patients
Disease control Recruiting nowThis study tests an experimental drug called IMC-001 in 30 adults with advanced solid tumors that have many genetic mutations (TMB-H). The goal is to see if the drug can shrink tumors and control the disease. Participants must have a tumor sample available for testing and at leas…
Phase: PHASE2 • Sponsor: ImmuneOncia Therapeutics Inc. • Aim: Disease control
Last updated May 26, 2026 04:35 UTC
-
New hope for advanced cancer: IMC-002 enters human trials
Disease control Recruiting nowThis early-stage study tests a new drug called IMC-002 in about 62 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also measure how the drug moves through the body…
Phase: PHASE1 • Sponsor: ImmuneOncia Therapeutics Inc. • Aim: Disease control
Last updated May 18, 2026 12:12 UTC